Expression of heparanase, Mdm2, and erbB2 in ovarian cancer

被引:0
|
作者
Ginath, S
Menczer, J
Friedmann, Y
Aingorn, H
Aviv, A
Tajima, K
Dantes, A
Glezerman, M
Vlodavsky, I
Amsterdam, A [1 ]
机构
[1] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel
[2] Holon & Sackler Fac Med, Edith Wolfson Med Ctr, Gynecol Oncol Unit, Dept Obstet & Gynecol, Tel Aviv, Israel
[3] Hebrew Univ Jerusalem, Hadassah Hosp, Dept Oncol, IL-91120 Jerusalem, Israel
关键词
heparanase; Mdm2; erbB2; apoptosis; ovarian cancer;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian cancer is the most lethal of gynecological malignancies. Yet early diagnosis and prognosis are far from being satisfactory. Degradation of heparan sulfate proteoglycans by heparanase appears to play an important role in the invasiveness of tumor cells through the basement membrane and into the extracellular matrix. Recent cloning of the heparanase gene and generation of monoclonal antibodies against the enzyme permit to examine tumor cell expression of the enzyme. The aim of the present study was to assess heparanase activity and localization in various subtypes of epithelial ovarian cancer in correlation with oncogene expression. Histologically confirmed malignant ovarian tissue from ten women and tissue from 2 benign ovarian tumors and 4 normal ovaries were assessed for heparanase presence, activity and localization, incidence of apoptosis and expression of the oncogenes erbB2 and Mdm2. Heparanase immunohistostaining and activity were present in mucinous carcinomas and were more intense than in endometrioid and in serous carcinomas. The lowest activity was observed in benign ovarian tumors and normal ovaries. In ovarian carcinomas the enzyme was intensely concentrated in the cytoplasm of the cancerous cells. In contrast, in normal ovaries and benign tumors the enzyme was predominantly localized in endothelial cells lining blood capillaries. The rate of apoptosis was considerably higher in mucinous and endometrioid carcinomas, and was lower in serous and primary peritoneal carcinomas. Extremely high concentration of heparanase was often demonstrated in apoptotic cells. Endometrioid and serous carcinomas showed high expression of Mdm2 and erbB2 while mucinous carcinomas showed low expression. In benign ovarian tumors and normal ovaries the expression of both oncoproteins was extremely low. In conclusion ovarian carcinomas demonstrate higher levels of heparanase than benign tumors and normal ovaries suggesting that the enzyme may play an important role in metastatic spread of the cancerous cells. Apoptosis may be a significant part of the mechanism of the enzyme release into the extacellular space. Although heparanase activity seems to play an essential role in tumor progression, expression of oncogenes, such as erbB2 and Mdm2 seems to play the dominant role in the development of ovarian cancer.
引用
收藏
页码:1133 / 1144
页数:12
相关论文
共 50 条
  • [11] MDM2 SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk
    Krekac, Daniel
    Brozkova, Kristyna
    Knoflickova, Dana
    Hrstka, Roman
    Muller, Petr
    Nenutil, Rudolf
    Vojtesek, Borivoj
    ONCOLOGY, 2008, 74 (1-2) : 84 - 87
  • [12] LASP-1 interacts with ErbB2 in ovarian cancer cells
    Sidhanth, Chirukandath
    Bindhya, Sadhanandhan
    Shabna, Aboo
    Krishnapriya, Shyama
    Manasa, Pacharla
    Nagare, Rohit Pravin
    Joshua, Thanda
    Sneha, Smarkan
    Murhekar, Kanchan
    Ganesan, Trivadi Sundaram
    BIOCHEMICAL JOURNAL, 2022, 479 (01) : 23 - 38
  • [13] Endocytic degradation of ErbB2 mediates the effectiveness of neratinib in the suppression of ErbB2-positive ovarian cancer
    Wang, Shanshan
    Zhang, Jinrui
    Wang, Taishu
    Ren, Feng
    Liu, Xiuxiu
    Lu, Yongqi
    Xu, Linying
    Zhang, Yang
    Wang, Duchuang
    Xu, Lu
    Wu, Yueguang
    Liu, Fang
    Li, Qiong
    Zaky, Mohamed Y.
    Liu, Shuyan
    Dong, Weijie
    Zou, Kun
    Zhang, Yingqiu
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2019, 117
  • [14] The organization and expression of the mdm2 gene
    Luna, RMDO
    Tabor, AD
    Eberspaecher, H
    Hulboy, DL
    Worth, LL
    Colman, MS
    Finlay, CA
    Lozano, G
    GENOMICS, 1996, 33 (03) : 352 - 357
  • [15] Subcellular localization of Mdm2 expression and prognosis of breast cancer
    Hyung Seok Park
    Ji Min Park
    Seho Park
    Junghoon Cho
    Seung Il Kim
    Byeong-Woo Park
    International Journal of Clinical Oncology, 2014, 19 : 842 - 851
  • [16] MDM2 Expression and Regulation in Prostate Cancer Racial Disparity
    Wang, Guimin
    Firoz, Elnaz F.
    Rose, Amy
    Blochin, Elen
    Christos, Paul
    Pollens, Danuta
    Mazumdar, Madhu
    Gerald, William
    Oddoux, Carole
    Lee, Peng
    Osman, Iman
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2009, 2 (04): : 353 - 360
  • [17] Subcellular localization of Mdm2 expression and prognosis of breast cancer
    Park, Hyung Seok
    Park, Ji Min
    Park, Seho
    Cho, Junghoon
    Kim, Seung Il
    Park, Byeong-Woo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (05) : 842 - 851
  • [18] ERBB2 mRNA expression in HER2-low breast cancer
    Teng, X.
    Li, X.
    Xu, S.
    Zhang, J.
    Bai, Y.
    Ba, X.
    Wu, Z.
    Liu, S.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S93 - S93
  • [19] Sarcoma of the spleen with MDM2 expression
    Hansen, T.
    Titze, U.
    Deeb, A.
    Eikoetter, B.
    Schuetz, M.
    Schildhaus, H. U.
    PATHOLOGE, 2016, 37 (04): : 367 - 370
  • [20] Role of laminin in ovarian cancer turner growth and metastasis via regulation of Mdm2 and Bcl-2 expression
    Yoshida, Y
    Hosokawa, K
    Dantes, A
    Kotsuji, F
    Kleinman, HK
    Amsterdam, A
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 18 (05) : 913 - 921